(I)

Scrial No. 10/561,199, filed 19 December 2005 Docket No. 1103326-0901 Page 3 of 8

Amendment to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application:

1. (Previously presented) A compound of formula L

or a pharmaceutically acceptable salt thereof.

2. (Previously presented) The compound according to claim 1, wherein the compound is 8-[(2,6-dimethylbenzyl)amino]-N-[(2S)-2-hydroxypropyl]-2,3-dimethylimidazo[1,2-a]pyridine-6-carboxamide mesylate salt.

- 3. (Currently amended) A process for the preparation of a compound according to claims 1 or 2, comprising the steps of:
- a) treating a compound of Formula II,

$$R^1$$
 N
 CH_3
 CH_3
 NH
 CH_3
 CH_3
 CH_3
 CH_3
 CH_3
 CH_3

wherein R¹ represents a C₁-C₆-alkoxy group or -NH₂,

with an aqueous acid or base under standard conditions; to form a compound of Formula III; and

b) reacting the compound of Formula III with a compound of Formula IV,

in the presence of <u>o-benzotriazol-1-yl-N,N,N',N'-tetramethyluronium tetrafluoroborate</u>

(TBTU) a-coupling reagent in an inert solvent under-standard conditions, to give a compound of

Formula I, and optionally converting the compound of Formula I to a pharmaceutically acceptable salt.

- 4. (Canceled)
- 5. (Previously presented) A pharmaceutical formulation comprising the compound according to claim 1 or 2 as active ingredient in combination with one or more pharmaceutically acceptable diluents or carriers.
- 6. (Canceled)
- 7. (Previously presented) A method for the treatment or inhibition of a gastric acid related disease, gastrointestinal inflammatory disease, heartburn, symptomatic GERD, erosive esophagitis, peptic ulcer disease, regurgitation, acid reflux disease, or nausea in a patient, the method comprising administering an effective amount of a compound according to claim 1 or 2 to the patient in need thereof.
- 8. (Previously presented) A compound of Formula III,